The Reality for Small and Medium-Sized Bio Companies: Shifting to Deficit Despite Revenue Growth

Recent data reveals that while the pharmaceutical and bio companies showed outward growth in the first quarter of this year, the gap between large corporations and small and medium-sized enterprises (SMEs) remains significant. According to the KoreaBIO Association, the total revenue for 82 listed bio-healthcare companies reached 9.468 trillion won, a 16.0% increase compared to the same period last year. Specifically, the pharmaceutical sector saw a 16.6% rise, and medical devices increased by 10.7%. However, this growth was predominantly driven by large corporations, which is a point of concern.

Growth Disparity Between Large Corporations and SMEs

While large pharmaceutical companies experienced a substantial revenue increase of 34.2%, mid-sized and small companies saw growth rates of only 7.7% and 7.6%, respectively. This disparity is linked to large corporations' high export ratio of 82.5%, with exports growing by 23.4%. Domestically, large corporations also led the expansion with a remarkable 128.2% increase. In contrast, SMEs, despite a 44.4% rise in domestic sales, faced a 14.3% decrease in exports, limiting their overall growth potential.

Unstable Profitability Despite Increased R&D Spending

Total research and development (R&D) expenditure in the first quarter amounted to 1.0395 trillion won, a 18.5% increase year-over-year. Large corporations' R&D spending rose by 17.3% to 321 billion won, and mid-sized companies also increased their R&D by 17.7% to 503.4 billion won. Notably, SMEs' R&D costs saw a significant jump of 38.5%, reaching 144.6 billion won.

However, the total R&D workforce grew by only 3% to 7,974 employees compared to the previous year, with SMEs showing the highest personnel growth rate at 7.2%. Despite these R&D investments, profitability indicators highlighted a stark divergence between large corporations and SMEs. Large companies achieved an operating profit margin of 40.4%, whereas SMEs plunged into a deficit, recording -31.5%.

Conclusion: Deepening Polarization and Challenges Ahead

In conclusion, while listed bio-healthcare companies maintained outward growth in the first quarter, the actual performance improvement was concentrated among large corporations with strong export bases. SMEs, on the other hand, are grappling with both increased R&D burdens and deteriorating profitability, leading to further polarization within the industry. It remains to be seen how small and medium-sized bio companies will navigate these challenging circumstances. This reality presents a significant concern for many. Sustainable development of the bio industry necessitates the growth and support of SMEs.